Business Context and Reporting Period
CalciMedica, Inc. (CALC) filed a Form 8-K on June 23, 2026, reporting the entry into a Material Definitive Agreement for a private placement of securities. The Company is a clinical-stage biopharmaceutical company focused on CRAC channel inhibition for pulmonary hypertension and other indications.
Key Financial Metrics and Capital Structure
- Transaction Type: Private placement of 18,673,429 Units.
- Unit Composition: Each Unit consists of (i) one share of Common Stock or one Pre-Funded Warrant, (ii) a right to receive one Series A Warrant upon stockholder approval, and (iii) a right to receive one Series B Warrant upon stockholder approval.
- Purchase Price: $0.8033 per Common Stock Unit; $0.8032 per Pre-Funded Warrant Unit.
- Gross Proceeds: Approximately $15.0 million upfront. Up to an additional $34 million potential gross proceeds if Warrants are fully exercised for cash.
- Insider Participation: Officers, directors, and certain affiliates (including CEO Rachel Leheny, CBO Eric Roberts, and CMO Sudarshan Hebbar) are participating in the purchase of an aggregate of 6,908,996 Units.
- Use of Proceeds: Funding research and development, working capital, and general corporate purposes.
- Liquidity Runway: Management estimates net proceeds combined with current cash will fund operations into the second half of 2027.
Material Changes and Strategic Updates
The filing details a strategic pivot to a focused pulmonary hypertension (PH) program and provides critical updates on regulatory interactions:
- Strategic Shift: Proceeds will advance a PH strategy utilizing the CRAC channel inhibition platform. The Company plans a capital-efficient Phase 1b proof-of-concept study of Auxora (intravenous) in pulmonary arterial hypertension (PAH), with data anticipated mid-2027.
- CM5480 Development: The Company anticipates Investigational New Drug (IND) application clearance for its oral candidate, CM5480, in mid-2027.
- FDA Update (KOURAGE Trial): The FDA reviewed a protocol amendment and interim safety data for the Phase 2 KOURAGE trial (Auxora in acute kidney injury) and issued no comments. This allows the Company to resume dosing patients. The trial was previously paused in January 2026 due to a mortality imbalance, which reviews attributed to baseline disease severity rather than drug toxicity.
- Acute Pancreatitis Program: The Company expects FDA feedback on the design of a potential pivotal program for Auxora in acute pancreatitis in the third quarter of 2026.
Guidance, Risks, and Contingencies
- Warrant Terms:
- Series A Warrants: Exercise price $0.8033; expire 18 months post-closing or 30 days after FDA IND clearance for CM5480 (whichever is earlier), subject to extension if stockholder approval is delayed.
- Series B Warrants: Exercise price $1.00; expire five years post-closing.
- Ownership Limitations: Beneficial ownership limitations of 19.99% apply to Pre-Funded Warrants and Warrants.
- Regulatory Risks: While the FDA has not placed a clinical hold on the KOURAGE trial, the Company must successfully execute the revised protocol. Future clinical results may not be indicative of future success.
- Capital Risks: The Company may not receive additional proceeds if Warrants are not exercised. The ability to satisfy closing conditions and obtain stockholder approval for Warrants is not guaranteed.
- Forward-Looking Statements: The filing contains numerous forward-looking statements regarding clinical timelines, regulatory approvals, and financial runway, which are subject to significant risks and uncertainties.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received from the Private Placement.
- Confirm the status of the stockholder vote required to issue the Series A and Series B Warrants.
- Monitor the resumption of patient dosing in the KOURAGE trial and any subsequent safety data releases.
- Track the timeline for the FDA IND clearance of CM5480 and the initiation of the Auxora Phase 1b PAH study.
- Review the Company's cash burn rate to validate the runway estimate into the second half of 2027.